Lung Cancer | Specialty

Timing and Utility of Next-Generation Sequencing

July 1st 2015

Importance of Identifying the Primary Tumor Type

July 1st 2015

CancerTYPE ID and Next-Generation Sequencing

July 1st 2015

Tumor Type Identification With CancerTYPE ID

July 1st 2015

Gene Testing Platforms for Diagnosis and Treatment Selection

July 1st 2015

Impact of Diagnostic Testing in Oncology

July 1st 2015

Pembrolizumab Priority Review, Benefits of Early Palliative Care, and More

June 13th 2015

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

2015 ASCO Annual Meeting Highlights

June 5th 2015

FDA Schedules ODAC Meeting for Necitumumab in NSCLC

June 3rd 2015

The FDA has scheduled an ODAC advisory hearing to discuss the biologics license application for necitumumab in combination with gemcitabine and cisplatin as a first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer.

FDA Grants Priority Review to Pembrolizumab in Lung Cancer

June 2nd 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

Dr. Socinski on Nivolumab in NSCLC

June 2nd 2015

Mark A. Socinski, MD, professor of Medicine and Cardiothoracic Surgery, director, Lung Cancer Section, Division of Hematology/Oncology, clinical associate director, Lung SPORE, co-director, UPMC Lung Cancer Center of Excellence, co-leader, UPCI Lung Cancer Program, discusses a phase III study which examined nivolumab in non-small cell lung cancer (NSCLC).

Dr. Spira on Atezolizumab in the POPLAR Study for NSCLC

June 2nd 2015

Alexander Spira, MD, PhD, FACP, medical oncology, hematology, Virginia Cancer Specialists, discusses the POPLAR study for non-small cell lung cancer (NSCLC).

Numerous NSCLC Studies Offer Optimism for New Therapies

May 31st 2015

Novel targeted therapies against ALK, BRAF, and RET have demonstrated promising outcomes in molecularly-defined patients with non-small cell lung cancer.

Atezolizumab Doubles OS in PD-L1-Positive NSCLC

May 31st 2015

Treatment with atezolizumab doubled overall survival compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.

MEDI4736, Tremelimumab Combo Active in Pretreated NSCLC

May 31st 2015

An immunotherapy combination demonstrated "high levels of clinical activity" in previously treated non-small cell lung cancer across a range of doses.

Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes

May 29th 2015

Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.

New Genomic Test Will Benefit Patients Being Screened for Lung Cancer

May 26th 2015

New England Journal of Medicine Publishes Study Co-Led by Hollings Cancer Center Researcher Showing Potential of New Genomic Test In Lung Screening.

Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLC

May 25th 2015

The definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.

Dr. Eric Haura on New Biomarker Assay System for Lung Cancer

May 11th 2015

Eric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.